Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 16;73(4):751-752.
doi: 10.1093/cid/ciab010.

US FDA's Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication

Roger M Echols  1 , Tsutae Nagata  1
Affiliations
Comment

US FDA's Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication

Roger M Echols et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Naseer S, Weinstein EA, Rubin DB, et al. U.S. Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja). Clin Infect Dis 2021; 72:e11003–11. - PubMed
    1. Fetroja® Prescribing Information: Drugs@FDA, Reference ID: 4676517. revised 20 September 2020.
    1. FDA identified breakpoints, cefiderocol injection. Available at: https://www.fda.gov/drugs/development-resources/cefiderocol-injection. Accessed 16 Jan 2021.
    1. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. L ancet Infect Dis 2020; doi: 10.1016/S1473-3099(20)30796-9. - DOI - PubMed
    1. Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2020; doi: 10.1016/S1473-3099(20)30731-3. - DOI - PubMed